Last reviewed · How we verify

NCT03530449

Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module

Terminated Last updated 28 February 2019
What this trial tests

trial testing OCT Angiography in Retinal Vascular in 39 participants. Terminated before completion.

Timeline
30 April 2018
Primary endpoint
15 September 2018
15 September 2018

Quick facts

Lead sponsorHeidelberg Engineering GmbH
StatusTerminated
Study typeOBSERVATIONAL
Enrollment39
Start date30 April 2018
Primary completion15 September 2018
Estimated completion15 September 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Heidelberg Engineering GmbH

Who can join

22 and older, any sex, with Retinal Vascular or Normal Eyes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Repeatability and Reproducibility of OCTA Image Quality with the Heidelberg Engineering SPECTRALIS

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of OCT Angiography

Trials testing the same drug.

Other Heidelberg Engineering GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03530449.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing